Opportunity Information: Apply for RFA AG 13 015
Apply for RFA AG 13 015
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Alzheimers Disease Prevention Trials (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866 Aging Research.
- This funding opportunity was created on Dec 12, 2012 and posted on Oct 15, 2012.
- Applicants must submit their applications by Jan 14, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $45,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $4,500,000.00 in funding.
- Eligible applicants include: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) For profit organizations other than small businesses County governments Private institutions of higher education Small businesses Public housing authorities/Indian housing authorities Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Public and State controlled institutions of higher education Special district governments State governments Native American tribal governments (Federally recognized) Independent school districts Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Alzheimers Disease Prevention Trials (R01) funding opportunity (RFA-AG-13-015) is a National Institutes of Health (NIH) grant program focused on supporting rigorous clinical prevention trials aimed at stopping or delaying Alzheimers disease (AD) before dementia develops. The central goal is to make it possible to test well-justified pharmacological and non-pharmacological interventions in people who are not yet symptomatic but are considered at elevated risk for AD, as well as in individuals with Mild Cognitive Impairment (MCI). By moving candidate interventions into carefully designed trials in these earlier stages, the initiative is meant to identify practical and scientifically credible paths to preventing AD or slowing progression along the AD continuum.
This opportunity uses the NIH R01 research project grant mechanism, which generally supports discrete, hypothesis-driven projects with clearly defined aims, methods, and milestones. It falls under the health research activity category and is associated with CFDA 93.866 (Aging Research). The program is explicitly set up to fund prevention trials, meaning the emphasis is not simply on observational studies or basic discovery, but on interventional testing designed to produce interpretable evidence about whether an approach can reduce risk, delay onset, or slow early cognitive decline consistent with AD prevention objectives.
From a funding standpoint, NIH estimated total program funding at about $45,000,000, with an award ceiling of $4,500,000. Cost sharing or matching is not required, which is typical for NIH research grants and lowers the barrier for participation by institutions that may not have large discretionary resources. Key dates indicate the announcement was posted October 15, 2012, created December 12, 2012, with an original closing date of January 13, 2013 and a current closing date of January 14, 2013; the archive date is February 14, 2013, meaning it is no longer active as an open solicitation but remains a useful reference for understanding NIH priorities and expectations for AD prevention trial proposals.
Eligibility is broad and includes many organization types that commonly participate in clinical research, such as public and private institutions of higher education, nonprofit organizations (including but not limited to 501(c)(3) entities), for-profit organizations other than small businesses, and small businesses, as well as state, county, city/township, and special district governments, independent school districts, and public or Indian housing authorities. The opportunity also welcomes applications from tribal governments (federally recognized) and other tribal organizations, and it explicitly includes a wide set of mission-driven and capacity-building institutions such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and faith-based or community-based organizations. Importantly, non-U.S. entities are eligible to apply, including foreign organizations and foreign institutions, and foreign components (as defined by NIH policy) are allowed, which reflects the global nature of AD research and the value of diverse populations and research settings in prevention trials.
Administratively, the sponsoring agency is NIH, and the public-facing link to the full announcement is provided through the NIH grants guide. The contact pathway listed is through the NIH Office of Extramural Research (OER) webmaster for technical difficulties accessing or linking to the announcement, which suggests that programmatic or scientific questions would normally be handled through the usual NIH channels described in the full RFA text. Overall, the opportunity is best understood as a targeted NIH effort to accelerate the translation of promising AD prevention strategies into well-controlled trials in at-risk and MCI populations, with substantial potential budgets to support the complexity and scale typically required for prevention-oriented clinical studies.
FAQs: Alzheimer's Disease Prevention Trials (R01) - RFA-AG-13-015
What is this funding opportunity?
This is the Alzheimer's Disease Prevention Trials (R01) funding opportunity (RFA-AG-13-015), a National Institutes of Health (NIH) grant program intended to support rigorous clinical prevention trials that aim to stop or delay Alzheimer's disease (AD) before dementia develops.
What is the main goal of the program?
The central goal is to make it possible to test well-justified pharmacological and non-pharmacological interventions in people who are not yet symptomatic but are considered at elevated risk for AD, as well as in individuals with Mild Cognitive Impairment (MCI). The broader intent is to identify practical and scientifically credible ways to prevent AD or slow progression along the AD continuum.
What type of research does this opportunity emphasize?
The emphasis is on interventional prevention trials designed to produce interpretable evidence about whether an approach can reduce risk, delay onset, or slow early cognitive decline consistent with AD prevention objectives. It is not positioned as a program for observational studies or basic discovery alone.
What NIH grant mechanism is used?
The opportunity uses the NIH R01 research project grant mechanism, which generally supports discrete, hypothesis-driven projects with clearly defined aims, methods, and milestones.
Is this opportunity focused on clinical trials?
Yes. It is explicitly set up to fund prevention trials, meaning clinical trial-style interventional testing in earlier stages of disease risk or impairment (including at-risk individuals and those with MCI).
Who is the target study population for these prevention trials?
The opportunity highlights trials in (1) individuals not yet symptomatic but considered at elevated risk for Alzheimer's disease, and (2) individuals with Mild Cognitive Impairment (MCI).
What kinds of interventions are in scope?
The program is intended to support testing of both pharmacological and non-pharmacological interventions, as long as they are well-justified and suitable for rigorous prevention trial designs.
What is the activity category and CFDA number associated with this program?
It falls under the health research activity category and is associated with CFDA 93.866 (Aging Research).
How much funding did NIH estimate for the program overall?
NIH estimated total program funding at about $45,000,000.
What is the maximum award amount (ceiling) for a single award?
The award ceiling is $4,500,000.
Is cost sharing or matching required?
No. Cost sharing or matching is not required.
When was the announcement posted and created?
The announcement was posted on October 15, 2012, and created on December 12, 2012.
What were the closing dates for the opportunity?
The original closing date was January 13, 2013, and the current closing date is January 14, 2013.
Is this funding opportunity still active?
No. The archive date is February 14, 2013, which indicates it is no longer active as an open solicitation. It remains useful as a reference for NIH priorities and expectations for AD prevention trial proposals.
Which agency is sponsoring this opportunity?
The sponsoring agency is the National Institutes of Health (NIH).
Where can applicants find the full announcement?
The full announcement is available via the NIH grants guide (the public-facing link is provided through that NIH channel).
Who is eligible to apply?
Eligibility is broad and includes public and private institutions of higher education; nonprofit organizations (including but not limited to 501(c)(3) entities); for-profit organizations (including small businesses and for-profit organizations other than small businesses); and various government entities such as state, county, city/township, and special district governments, independent school districts, and public or Indian housing authorities.
Are tribal governments and tribal organizations eligible?
Yes. Tribal governments (federally recognized) and other tribal organizations are included among eligible applicants.
Does the opportunity explicitly include certain mission-driven or capacity-building institutions?
Yes. The eligibility language explicitly includes institutions such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and faith-based or community-based organizations.
Can non-U.S. organizations apply?
Yes. Non-U.S. entities are eligible to apply, including foreign organizations and foreign institutions.
Are foreign components allowed under NIH policy for this opportunity?
Yes. Foreign components (as defined by NIH policy) are allowed.
What does it mean that this opportunity is aimed at prevention trials rather than observational studies?
Based on the description, the program prioritizes interventional testing intended to determine whether an intervention can reduce risk, delay onset, or slow early cognitive decline. In other words, the focus is on testing strategies in a trial setting rather than only observing outcomes without assigning an intervention.
What is the listed contact pathway for access or linking issues?
The listed contact pathway is through the NIH Office of Extramural Research (OER) webmaster for technical difficulties accessing or linking to the announcement.
Does the provided information include a scientific or program contact for research questions?
The provided information notes the OER webmaster for technical issues and indicates that programmatic or scientific questions would normally be handled through the usual NIH channels described in the full RFA text.
Why does this opportunity matter for Alzheimer's research strategy?
It reflects a targeted NIH effort to accelerate translation of promising AD prevention strategies into carefully designed, well-controlled trials in at-risk and MCI populations, recognizing that prevention-oriented studies often require substantial budgets due to their complexity and scale.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Health
Next opportunity: Agriculture and Food Research Initiative Foundational Program
Previous opportunity: Sea based Aviation National Naval Responsibility Propulsion Focus Area
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AG 13 015
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AG 13 015) also looked into and applied for these:
| Funding Opportunity |
|---|
| Alzheimers Disease Phase I Clinical Trials (R01) Apply for RFA AG 13 016 Funding Number: RFA AG 13 016 Agency: National Institutes of Health Category: Health Funding Amount: $800,000 |
| Shared Instrumentation Grant Program (S10) Apply for PAR 13 008 Funding Number: PAR 13 008 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Dynamics of Host Associated Microbial Communities (R01) Apply for RFA GM 14 001 Funding Number: RFA GM 14 001 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Secondary Dataset Analyses in Heart, Lung, and Blood Diseases and Sleep Disorders (R21) Apply for PAR 13 009 Funding Number: PAR 13 009 Agency: National Institutes of Health Category: Health Funding Amount: $75,000 |
| Mentored Research Scientist Development Award in Metabolomics (K01) Apply for RFA RM 12 025 Funding Number: RFA RM 12 025 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Health System Strengthening Project Apply for APS 391 13 000001 Funding Number: APS 391 13 000001 Agency: Pakistan USAID Islamabad Category: Health Funding Amount: $21,900,000 |
| Limited Competition Brain Tissue Resource Center for Alcohol Research (R28) Apply for PAR 13 011 Funding Number: PAR 13 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Initiative to Maximize Research Education in Genomics Courses (R25) Apply for PAR 13 012 Funding Number: PAR 13 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Agir pour la Planification Familiale AGIR PF Apply for RFA 624 13 000002 Funding Number: RFA 624 13 000002 Agency: Ghana USAID Accra Category: Health Funding Amount: $29,000,000 |
| Alzheimers Disease Therapeutics Program (U01) Apply for RFA AG 13 014 Funding Number: RFA AG 13 014 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Epigenomics of Virus Associated Oral Diseases (R21) Apply for RFA DE 13 003 Funding Number: RFA DE 13 003 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Epigenomics of Virus Associated Oral Diseases (R01) Apply for RFA DE 13 002 Funding Number: RFA DE 13 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Collaborative Network for Clinical Research on Immune Tolerance (UM1) Apply for RFA AI 12 043 Funding Number: RFA AI 12 043 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Tuberculosis Research Units (U19) Apply for RFA AI 12 045 Funding Number: RFA AI 12 045 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| AHRQ Conference Grant Program (R13) Apply for PA 13 017 Funding Number: PA 13 017 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Limited Competition Collaborative Partnership to Advance Global Biomedical Research Programs (U01) Apply for RFA AI 12 055 Funding Number: RFA AI 12 055 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Age Related Changes in Osteoimmunology (R01) Apply for RFA AG 13 017 Funding Number: RFA AG 13 017 Agency: National Institutes of Health Category: Health Funding Amount: $125,000 |
| FY13 FY14 Department of Defense HIV/AIDS Prevention Program Military Specific HIV/AIDS Prevention, Care, and Treatment Program for non PEPFAR (Presidents Emergency Plan for AIDS Relief) Funded Countries Apply for DHAPP BAA 13 001 Funding Number: DHAPP BAA 13 001 Agency: Naval Supply Systems Command Category: Health Funding Amount: Case Dependent |
| Service Area Competition Additional Area (SAC AA) Tuskegee, Alabama Apply for HRSA 13 260 Funding Number: HRSA 13 260 Agency: Health Resources and Services Administration Category: Health Funding Amount: $1,398,873 |
| Nurse Anesthetist Traineeship Program (NAT) Apply for HRSA 13 187 Funding Number: HRSA 13 187 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AG 13 015", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.